Abterra Biosciences is dedicated to advancing the field of antibody therapeutics through cutting-edge technology. The company employs next-generation sequencing, mass spectrometry, and machine learning to map antibody responses comprehensively. This approach enables the rapid identification of superior therapeutic antibodies for infectious diseases and cancer. With a focus on truly human antibody therapeutics, Abterra Bio aims to revolutionize how these treatments are developed.
Abterra Biosciences has assembled an interdisciplinary team of data scientists and biologists to drive innovation in antibody therapeutics. Their technology is built on decades of experience, positioning them as a leader in the industry. By leveraging advanced methodologies, Abterra Bio has made significant strides in identifying effective therapeutic antibodies, contributing to improved healthcare outcomes.
